This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, G. K. Articles by Ohnuma, T. Search for Related Content PubMed PubMed Citation Articles by Schwartz, G. K. Articles by Ohnuma, T.

Protein Kinase C Activity and Multidrug Resistance in MOLT-3 Human Lymphoblastic Leukemia Cells Resistant to Trimetrexate¹

Department of Neoplastic Diseases and the Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029

It has been suggested that protein kinase C (PKC) plays a role in multidrug resistance (MDR). In this study we assayed PKC activity in MOLT-3 human acute lymphoblastic leukemia cells and found an approximately 50% decrease in activity in MDR sublines made resistant to the lipophilic antifolate trimetrexate, when compared with trimetrexate-sensitive parent cells. The PKC activity of a methotrexate-resistant subline without MDR (MOLT-3/MTX_10,000) was identical to that of parent cells. Although a downward trend was noted in PKC activity in the membrane fraction of cells with increasing trimetrexate resistance, there was no absolute correlation between the degree of MDR and the relative decrease in PKC activity. Using the same method, we also confirmed an over 6-fold increase in PKC activity in the MDR human breast cancer subline MCF-7/DOX^R when compared with the sensitive parent cell line, MCF-7/WT.

Because of this divergent relationship between relative PKC activity and MDR, we tested the effect of PKC inhibition and activation on drug resistance. The PKC inhibitor staurosporine, at both subtoxic and toxic concentrations as well as at concentrations shown to be inhibitory to PKC, failed to increase drug resistance of parent and resistant MOLT-3 cells and decrease drug resistance of MCF-7/WT and MCF-7/DOX^R cells. Short-term exposure to 3-phorbol-12-myristate-13-acetate, which activated PKC 7.0-fold and 4.7-fold, respectively, in the membrane of MOLT-3 and resistant cells, resulted in small (1.3- to 1.8-fold), approximately equivalent, increases (rather than decreases) in resistance to doxorubicin, whereas for vincristine no consistent trend was observed. Identical results were also obtained with phorbol-12,13-dibutyrate.

These results indicate that PKC activity can be decreased and increased in MDR cells. Both staurosporine inhibition and phorbol ester activation failed to produce changes in drug resistance that would be considered consistent with the resulting degree of PKC activity. Short-term phorbol ester exposure can change the sensitivity of the cells to doxorubicin without changing the relative drug resistance. PKC activity in these cells may then be unrelated to MDR.

¹ This work was supported in part by the T. J. Martell Foundation for Leukemia and Cancer Research, New York, NY; by the Chemotherapy Foundation, Inc., New York, NY; and by a grant from Kyowa Hakko Kogyo Co., Ltd., Japan.

² To whom requests for reprints should be addressed, at Solid Tumor Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

Received 2/ 8/80. Accepted 9/28/90.

This article has been cited by other articles:

				R. L. Fine, T. C. Chambers, and C. W. Sachs P-Glycoprotein, Multidrug Resistance and Protein Kinase C Oncologist, August 1, 1996; 1(4): 261 - 268. [Abstract] [Full Text] [PDF]

				R. Fine, T. Chambers, and C. Sachs P-glycoprotein, multidrug resistance and protein kinase C Stem Cells, January 1, 1996; 14(1): 47 - 55. [Abstract]